Advertisement
Screener

RAFAEL HOLDINGS, INC. (RFL) Business Acquisition, Pro Forma Revenue

2.0 / 5 stars · 27/66 Roast Me

RAFAEL HOLDINGS, INC. Business Acquisition, Pro Forma Revenue

RAFAEL HOLDINGS, INC. (RFL) reported Business Acquisition, Pro Forma Revenue of $758.00 thousand for the 6-month period ending 2026-01-31, per its 10-Q filed 2026-03-16.

Financial Statements › Income Statement › Other Income

us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2026-06-11

  • RAFAEL HOLDINGS, INC. business acquisition, pro forma revenue for the quarter ending 2025-07-31 was $816.00K, a 183.33% increase year-over-year.
  • RAFAEL HOLDINGS, INC. business acquisition, pro forma revenue for the quarter ending 2025-04-30 was $472.00K, a 12.27% decline year-over-year.
  • RAFAEL HOLDINGS, INC. business acquisition, pro forma revenue for the quarter ending 2025-01-31 was $397.00K.
  • RAFAEL HOLDINGS, INC. business acquisition, pro forma revenue for the quarter ending 2024-10-31 was $362.00K, a 432.35% increase year-over-year.
  • RAFAEL HOLDINGS, INC. business acquisition, pro forma revenue for fiscal 2025 was $2.05M, a 15.66% increase from fiscal 2024.
  • RAFAEL HOLDINGS, INC. business acquisition, pro forma revenue for fiscal 2024 was $1.77M, a 534.05% increase from fiscal 2023.
  • RAFAEL HOLDINGS, INC. business acquisition, pro forma revenue for fiscal 2023 was $279.00K.
Period endBusiness Acquisition, Pro Forma Revenue 3 monthBusiness Acquisition, Pro Forma Revenue 3 month as first filedBusiness Acquisition, Pro Forma Revenue 6 monthBusiness Acquisition, Pro Forma Revenue 9 monthBusiness Acquisition, Pro Forma Revenue 9 month as first filedBusiness Acquisition, Pro Forma Revenue 12 monthBusiness Acquisition, Pro Forma Revenue 12 month as first filed
2026-01-31$758.00K
10-Q · filed 2026-03-16
2025-07-31$816.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29
$1.29M
derived: sum of 2 quarters · filed 2026-06-11
$1.69M
derived: sum of 3 quarters · filed 2026-06-11
$2.05M
10-K · filed 2025-10-29
2025-04-30$472.00K
10-Q · filed 2026-06-11
$869.00K
derived: sum of 2 quarters · filed 2026-06-11
$1.23M
10-Q · filed 2026-06-11
$1.52M
derived: sum of 4 quarters · filed 2026-06-11
2025-01-31$397.00K
10-Q · filed 2026-03-16
$759.00K
derived: sum of 2 quarters · filed 2026-03-16
$1.05M
derived: sum of 3 quarters · filed 2026-03-16
$1.58M
derived: sum of 4 quarters · filed 2026-03-16
2024-10-31$362.00K
10-Q · filed 2025-12-12
$650.00K
derived: sum of 2 quarters · filed 2025-12-12
$1.19M
derived: sum of 3 quarters · filed 2025-12-12
2024-07-31$288.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29
$826.00K
derived: sum of 2 quarters · filed 2025-10-29
$1.77M
10-K · filed 2025-10-29
$637.00K
10-K · filed 2024-11-07
2024-04-30$538.00K
10-Q · filed 2025-06-11
$337.00K
10-Q · filed 2024-06-14
$1.48M
10-Q · filed 2025-06-11
$472.00K
10-Q · filed 2024-06-14
2023-10-31$68.00K
10-Q · filed 2024-12-11
$136.00K
derived: sum of 2 quarters · filed 2024-12-20
$207.00K
derived: sum of 3 quarters · filed 2024-12-20
2023-07-31$68.00K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20
$139.00K
derived: sum of 2 quarters · filed 2024-12-20
$279.00K
10-K/A · filed 2024-12-20
2023-04-30$71.00K
10-Q · filed 2024-06-14
$211.00K
10-Q · filed 2024-06-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aditxt, Inc. (ADTX)United States$0.000B
CDT Equity Inc. (CDT)United States$0.000B-0.01
Protagenic Therapeutics, Inc.\new (PTIX)United States$0.001B
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
Nexentis Technologies Inc. (NXTS)$0.002B
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B